<DOC>
	<DOCNO>NCT03011372</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety INCB054828 subject myeloid/lymphoid neoplasms fibroblast growth factor receptor ( FGFR ) 1 rearrangement .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety INCB054828 Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Documented lymphoid myeloid neoplasm 8p11 rearrangement know lead FGFR1 activation , base standard diagnostic cytogenetic evaluation perform locally , sign inform consent study . Subjects must relapsed/refractory . Prior stem cell transplantation allow . Life expectancy â‰¥ 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Prior receipt selective FGFR inhibitor . History and/or current evidence ectopic mineralization/calcification , include limited soft tissue , kidney , intestine , myocardium , lung , except calcify lymph node asymptomatic arterial cartilage/tendon calcification . Current evidence corneal disorder/keratopathy , include limited bullous/band keratopathy , corneal abrasion , inflammation/ulceration , keratoconjunctivitis , confirm ophthalmologic examination . Use potent cytochrome P450 3A4 inhibitor inducer within 14 day 5 halflives ( whichever short ) first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myeloid neoplasm</keyword>
	<keyword>fibroblast growth factor receptor inhibitor</keyword>
	<keyword>FGFR1 rearrangement</keyword>
	<keyword>8p11</keyword>
	<keyword>eosinophilia</keyword>
	<keyword>eosinophilic syndrome</keyword>
	<keyword>Lymphoid neoplasm</keyword>
</DOC>